206 related articles for article (PubMed ID: 34805996)
1. Nigral diffusivity, but not free water, correlates with iron content in Parkinson's disease.
Langley J; Huddleston DE; Hu X
Brain Commun; 2021; 3(4):fcab251. PubMed ID: 34805996
[TBL] [Abstract][Full Text] [Related]
2. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
[TBL] [Abstract][Full Text] [Related]
3. Detecting dopaminergic neuronal degeneration using diffusion tensor imaging in a rotenone-induced rat model of Parkinson's disease: fractional anisotropy and mean diffusivity values.
Liu LX; Du D; Zheng T; Fang Y; Chen YS; Yi HL; He QY; Gao DW; Shi QL
Neural Regen Res; 2017 Sep; 12(9):1485-1491. PubMed ID: 29089995
[TBL] [Abstract][Full Text] [Related]
4. Substantia nigra locations of iron-content, free-water and mean diffusivity abnormalities in moderate stage Parkinson's disease.
Arribarat G; Pasternak O; De Barros A; Galitzky M; Rascol O; Péran P
Parkinsonism Relat Disord; 2019 Aug; 65():146-152. PubMed ID: 31182373
[TBL] [Abstract][Full Text] [Related]
5. Diffusion tensor imaging of nigral degeneration in Parkinson's disease: A region-of-interest and voxel-based study at 3 T and systematic review with meta-analysis.
Schwarz ST; Abaei M; Gontu V; Morgan PS; Bajaj N; Auer DP
Neuroimage Clin; 2013; 3():481-8. PubMed ID: 24273730
[TBL] [Abstract][Full Text] [Related]
6. In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts.
Hwang KS; Langley J; Tripathi R; Hu XP; Huddleston DE
PLoS One; 2023; 18(4):e0282684. PubMed ID: 37053195
[TBL] [Abstract][Full Text] [Related]
7. Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study.
Ofori E; Pasternak O; Planetta PJ; Burciu R; Snyder A; Febo M; Golde TE; Okun MS; Vaillancourt DE
Neurobiol Aging; 2015 Feb; 36(2):1097-104. PubMed ID: 25467638
[TBL] [Abstract][Full Text] [Related]
8. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
[TBL] [Abstract][Full Text] [Related]
9. Free-water imaging in Parkinson's disease and atypical parkinsonism.
Planetta PJ; Ofori E; Pasternak O; Burciu RG; Shukla P; DeSimone JC; Okun MS; McFarland NR; Vaillancourt DE
Brain; 2016 Feb; 139(Pt 2):495-508. PubMed ID: 26705348
[TBL] [Abstract][Full Text] [Related]
10. Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits.
Schuff N; Wu IW; Buckley S; Foster ED; Coffey CS; Gitelman DR; Mendick S; Seibyl J; Simuni T; Zhang Y; Jankovic J; Hunter C; Tanner CM; Rees L; Factor S; Berg D; Wurster I; Gauss K; Sprenger F; Seppi K; Poewe W; Mollenhauer B; Knake S; Mari Z; McCoy A; Ranola M; Marek K
Mov Disord; 2015 Dec; 30(14):1885-92. PubMed ID: 26260437
[TBL] [Abstract][Full Text] [Related]
11. Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study.
Ofori E; Krismer F; Burciu RG; Pasternak O; McCracken JL; Lewis MM; Du G; McFarland NR; Okun MS; Poewe W; Mueller C; Gizewski ER; Schocke M; Kremser C; Li H; Huang X; Seppi K; Vaillancourt DE
Mov Disord; 2017 Oct; 32(10):1457-1464. PubMed ID: 28714593
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
[TBL] [Abstract][Full Text] [Related]
13. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease.
Du G; Lewis MM; Styner M; Shaffer ML; Sen S; Yang QX; Huang X
Mov Disord; 2011 Aug; 26(9):1627-32. PubMed ID: 21618607
[TBL] [Abstract][Full Text] [Related]
14. Microstructural abnormalities of substantia nigra in Parkinson's disease: A neuromelanin sensitive MRI atlas based study.
Safai A; Prasad S; Chougule T; Saini J; Pal PK; Ingalhalikar M
Hum Brain Mapp; 2020 Apr; 41(5):1323-1333. PubMed ID: 31778276
[TBL] [Abstract][Full Text] [Related]
15. Diffusion Measure Changes of Substantia Nigra Subregions and the Ventral Tegmental Area in Newly Diagnosed Parkinson's Disease.
Shim JH; Baek HM
Exp Neurobiol; 2021 Oct; 30(5):365-373. PubMed ID: 34737241
[TBL] [Abstract][Full Text] [Related]
16. In vivo detection of lateral-ventral tier nigral degeneration in Parkinson's disease.
Huddleston DE; Langley J; Sedlacik J; Boelmans K; Factor SA; Hu XP
Hum Brain Mapp; 2017 May; 38(5):2627-2634. PubMed ID: 28240402
[TBL] [Abstract][Full Text] [Related]
17. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
[TBL] [Abstract][Full Text] [Related]
19. Progression marker of Parkinson's disease: a 4-year multi-site imaging study.
Burciu RG; Ofori E; Archer DB; Wu SS; Pasternak O; McFarland NR; Okun MS; Vaillancourt DE
Brain; 2017 Aug; 140(8):2183-2192. PubMed ID: 28899020
[TBL] [Abstract][Full Text] [Related]
20. Nigral volume loss in prodromal, early, and moderate Parkinson's disease.
Langley J; Hwang KS; Huddleston DE; Hu XP
medRxiv; 2023 Aug; ():. PubMed ID: 37645770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
